ADMA vs. SMMT, ITCI, GMAB, RDY, VTRS, MRNA, QGEN, ASND, ROIV, and RVMD
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
ADMA Biologics vs.
ADMA Biologics (NASDAQ:ADMA) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
ADMA Biologics received 102 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 72.05% of users gave ADMA Biologics an outperform vote while only 58.50% of users gave Summit Therapeutics an outperform vote.
ADMA Biologics has a net margin of 17.80% compared to Summit Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Summit Therapeutics' return on equity.
ADMA Biologics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500.
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, ADMA Biologics had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for ADMA Biologics and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.42 beat ADMA Biologics' score of 1.29 indicating that Summit Therapeutics is being referred to more favorably in the news media.
ADMA Biologics currently has a consensus target price of $24.25, indicating a potential upside of 18.64%. Summit Therapeutics has a consensus target price of $37.40, indicating a potential upside of 53.34%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than ADMA Biologics.
Summary
ADMA Biologics beats Summit Therapeutics on 13 of the 18 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:ADMA) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy ADMA Stock Free ADMA Stock Alerts